Overview

Pharmacokinetics of Islatravir in Participants With Severe Renal Impairment (MK-8591-026)

Status:
Completed

Trial end date:
2020-10-19

Target enrollment:

Participant gender:

Summary

This study will evaluate the general tolerability and pharmacokinetics (PK) of a single 60 mg dose of MK-8591 (Islatravir) in participants with severe renal insufficiency, compared to participants in good health.

Phase:

Phase 1

Details

Lead Sponsor:

Merck Sharp & Dohme Corp.

Treatments:

4'-ethynyl-2-fluoro-2'-deoxyadenosine
Islatravir